GlassScriptPhysician profile
Susana Bell
NPI 1770605008
$14,645.95
in general payments reported to CMS, 2019-2025
60 companies · $4,339 in 2025
The $4,339 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,418 · 2022: $2,146 · 2023: $2,852 · 2024: $3,890 · 2025: $4,339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,538.06 |
| Education | $543.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,203.72 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Janssen Biotech, INC. | $1,201.94 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Exelixis INC. | $1,003.85 | 2021-2025 | Cabometyx |
| Daiichi Sankyo INC. | $967.11 | 2022-2025 | Injectafer, Vanflyta, Enhertu |
| Seagen INC. | $661.06 | 2021-2025 | Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals LP | $643.46 | 2021-2025 | Enhertu, Tagrisso, Calquence |
| Sobi, INC | $586.51 | 2023-2025 | |
| Astellas Pharma US INC | $585.14 | 2023-2025 | Vyloy, Xospata, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $534.25 | 2021-2025 | Fruzaqla, Alunbrig, Iclusig |
| Lilly USA, LLC | $486.62 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Amgen INC. | $433.64 | 2021-2023 | Blincyto, Kyprolis, Xgeva |
| Pfizer INC. | $405.07 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $404.50 | 2022-2025 | |
| Genentech USA, INC. | $356.75 | 2021-2025 | Polivy, Phesgo, Tecentriq |
| Stemline Therapeutics INC. | $338.43 | 2023-2025 | Orserdu, Elzonris |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susana Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.